b
r
c
cyclophilin
cyp
ubiquit
protein
effect
cistran
isomer
pro
amid
bond
thu
crucial
protein
fold
cypa
preval
human
cyp
play
crucial
role
viral
infect
notabl
hcv
cyclophilin
shown
play
key
role
effect
replic
number
virus
differ
famili
drug
templat
cypa
inhibit
cyclosporin
csa
cyclic
undecapeptid
simultan
bind
cypa
ca
depend
phosphatas
calcineurin
cn
attenu
immun
respons
synthet
modif
csa
scaffold
allow
select
bind
cypa
cn
separ
thu
provid
access
novel
nonimmunosuppress
antivir
agent
sinc
initi
develop
cyclosporin
csa
immunosuppress
agent
prevent
allograph
reject
cyclophilin
cyp
inhibitor
explor
extens
last
four
decad
treat
wide
varieti
medicin
condit
includ
autoimmun
diseas
myocardi
infarct
ischemia
reperfus
viral
diseas
latter
focu
review
overview
cyp
structur
function
first
present
follow
evid
implic
role
cyp
viral
diseas
notabl
hcv
follow
discuss
csabas
cyp
inhibitor
includ
vivo
vitro
structureact
relationship
lead
discuss
cyp
inhibitor
current
develop
treatment
hepat
c
viru
cyclophilin
cyclophilin
cyp
class
protein
share
common
enzymat
activ
peptidylprolyl
isomeras
ppias
effect
cistran
isomer
amid
bond
ntermin
prolin
pro
residu
thu
play
regulatori
role
protein
fold
least
member
cyp
class
identifi
human
size
rang
small
singl
ppiasedomain
cyp
cypa
cypb
cypc
cypd
cypj
usacyp
larg
multidomain
protein
catalyt
ppias
activ
link
variou
addit
activ
fig
cypa
abundantli
express
member
class
repres
major
ppias
activ
cell
cypb
cyp
found
trace
level
addit
cyp
two
famili
protein
fkbp
parvulin
fig
describ
similar
ppias
activ
inhibit
ppias
activ
fkbp
either
rapamycin
shown
requir
immunosuppress
activ
compound
parvulin
respons
cistran
isomer
po
h
ser
po
h
thr
pro
bond
howev
much
less
well
studi
one
key
member
parvulin
class
interact
phosphoprotein
involv
cell
cycl
cancer
cell
howev
lack
potent
select
inhibitor
parvulin
limit
research
area
cyp
show
wide
differ
express
profil
cypa
found
predominantli
cytoplasm
restrict
local
observ
cypb
endoplasm
reticulum
cypd
mitochondri
inner
membran
cype
nucleu
nuclear
pore
studi
direct
function
character
cypa
cypb
cypd
report
last
year
howev
nativ
role
major
class
potenti
role
diseas
state
yet
elucid
sever
mechan
cyp
catalyz
cistran
isomer
xaapro
bond
propos
howev
current
accept
mode
catalysi
base
distort
planar
amid
bond
fig
bind
procontain
substrat
manner
twist
amid
bond
lead
lower
barrier
rotat
due
loss
amid
reson
import
hydrogen
bond
activ
site
residu
side
chain
cypa
prolyl
amid
nitrogen
facilit
format
pyramid
nitrogen
key
featur
isomer
notabl
mutat
result
catalyt
inact
form
cypa
use
extens
mechanist
probe
crystal
structur
analysi
sever
procontain
substrat
peptid
bound
human
cypa
reveal
ligand
evalu
bound
xaapro
bond
ci
conform
distort
planar
sinc
xaapro
amid
bond
resid
prefer
prefer
tran
conform
ke
propos
principl
role
cyp
facilit
tran
ci
isomer
ppias
activ
cyp
well
studi
sever
addit
role
cyp
also
describ
bind
either
cypa
cypb
extracellular
receptor
cypa
lead
activ
map
kinas
pathway
induct
matrix
metalloproteinas
mmp
product
role
cypa
inflammatori
chemotact
cytokin
act
receptor
reveal
use
murin
model
asthma
block
interact
csa
result
signific
decreas
neutrophil
eosinophil
migrat
improv
lung
patholog
role
extracellular
cyp
renal
fibrosi
ischemiareperfus
injuri
describ
key
activ
receptor
discoveri
cypa
requisit
bind
protein
immunosuppress
activ
csa
serv
place
cypa
firmli
within
sphere
immunolog
research
demonstr
binari
cypa
csa
complex
inhibit
calciumdepend
phosphatas
activ
calcineurin
cn
lead
inhibit
key
activ
tcell
provid
compel
explan
immunosuppress
activ
csa
sar
studi
perform
csa
allow
two
discret
face
ascrib
csa
reflect
affin
protein
affect
modif
variou
region
csa
fig
howev
expand
rang
activ
demonstr
csa
includ
mitochondri
function
cell
death
chemotaxi
motil
suggest
mechan
easili
ascrib
cn
inhibit
discoveri
new
csa
analog
retain
potent
bind
cypa
prevent
ternari
complex
format
cn
allow
biolog
cyp
probe
independ
immunosuppress
activ
furthermor
use
knockdown
genesilenc
techniqu
reveal
rich
expand
biolog
associ
cyp
virolog
emerg
import
focu
research
human
immunodefici
parasit
viru
caus
aid
depend
heavili
host
cellular
machineri
surviv
replic
infect
cypa
first
cellular
protein
ever
found
incorpor
virion
subsequ
signific
number
public
suggest
sever
role
cypa
hiv
life
cycl
independ
cn
inhibit
initi
report
csa
inhibit
surfac
although
first
report
specif
implic
cypa
involv
life
cycl
publish
five
year
later
report
endogen
cypa
coloc
gag
protein
cytoplasm
bind
specif
prorich
sequenc
capsid
domain
gag
xray
crystallographi
later
reveal
residu
capsid
bind
activ
site
cypa
subsequ
studi
shown
virion
produc
presenc
gag
mutat
cypa
bind
region
pressur
competit
cypa
inhibitor
less
infecti
wild
type
virion
cypa
incorpor
nascent
virion
assembl
bud
process
facilit
uncoat
capsid
support
suffici
revers
transcript
viral
genom
recent
studi
howev
suggest
cypa
infect
target
cell
cypa
virion
import
infect
shown
cypa
target
cell
increas
infect
inhibit
host
cell
restrict
factor
mount
part
innat
immun
respons
ordinarili
combat
invad
retrovirus
reduc
cypacapsid
interact
either
mutat
alter
bind
cypa
capsid
introduct
cypa
inhibitor
csa
shown
increas
suscept
restrict
recent
studi
suggest
cypa
bind
viral
protein
r
vpr
undergo
cistran
isomer
pro
residu
ntermin
region
activ
cypa
ultim
govern
function
express
vpr
need
transloc
viru
nucleu
induct
cell
cycl
arrest
apoptosi
infect
cell
summari
sever
stage
life
cycl
involv
cypa
understood
clearli
other
clearli
cypa
inhibitor
bound
cypa
alon
cn
would
potenti
effect
antihiv
therapeut
compound
develop
discuss
section
c
hepat
c
viru
first
report
hcv
inhibit
csa
emerg
even
predat
hcv
name
clinic
studi
hcv
infect
patient
undergo
liver
transplant
show
superior
virolog
respons
csa
combin
interferon
versu
interferon
alon
implic
cyp
inhibit
approach
hcv
therapi
csa
found
inhibit
hcv
cellculturebas
replicon
system
howev
immunosuppress
activ
csa
still
obscur
role
cyp
hcv
replic
initi
studi
identifi
cypb
andor
cypc
crucial
hcv
replic
howev
subsequ
report
indic
cypa
alon
crucial
replic
hcv
genotyp
complic
matter
recent
studi
suggest
hcv
replic
influenc
differ
stage
sever
cyp
includ
cypa
regul
transcript
translat
cypb
cypc
protein
conform
transport
cype
cyph
regul
mrna
splice
gener
host
protein
necessari
hcv
regul
translat
nonvesicular
transport
cholesterol
cochaperon
support
cypa
primari
cyp
involv
hcv
rna
replic
includ
demonstr
catalyt
ppias
activ
cypa
requir
effici
hcv
rna
replic
find
specif
bind
cypa
dissoci
addit
csabas
cyp
inhibitor
recent
consensu
emerg
cypa
like
princip
perhap
exclus
cyp
involv
hcv
replic
complex
role
cyp
differ
aspect
hcv
propag
consid
evid
support
bind
cypa
sever
hcv
protein
includ
publish
consist
find
vitro
resist
cyp
inhibitor
slow
emerg
associ
mutat
demonstr
knockdown
cypa
inhibit
replic
full
length
hcv
genom
significantli
effect
subgenom
replicon
system
support
idea
cypa
involv
interact
hcv
protein
detail
specif
role
cypa
hcv
replic
complex
recent
appear
howev
consensu
mechan
emerg
clear
cypa
essenti
compon
hcv
replic
complex
differ
model
propos
explain
requir
includ
role
activ
incorpor
replic
complex
versu
model
wherebi
cypa
preresid
crude
replic
complex
membran
fraction
serv
associ
assembl
replic
complex
clue
toward
understand
role
cypa
ppias
activ
might
play
hcv
rna
replic
present
bartenschlag
studi
rate
hcv
polyprotein
process
resist
mutat
cyp
inhibitor
alisporivir
occur
near
cleavag
site
polyprotein
result
delay
process
protein
impair
replic
activ
suggest
cypa
may
requir
allow
protein
achiev
requir
conform
allow
effect
cleavag
viru
may
escap
need
cypa
specif
locat
mutat
residu
close
cleavag
site
introduc
conform
flexibl
howev
come
cost
viru
impair
replic
capac
high
barrier
resist
cyp
inhibitor
may
result
need
multipl
viru
mutat
appear
escap
need
cypa
mediat
reorgan
mutat
incur
replic
fit
cost
recent
ciesek
cowork
explor
genet
variant
cypa
via
nonsynonym
singl
nucleotid
polymorph
snp
impact
hcv
replic
studi
show
sever
snp
present
human
popul
caus
deplet
intracellular
cypa
also
reduc
hcv
infect
summari
ampl
evid
hcv
life
cycl
depend
host
cell
cyp
perhap
multipl
process
case
cyp
inhibitor
particular
cypa
inhibitor
nonimmunosuppress
would
effect
antihcv
therapi
compound
develop
discuss
later
review
dengu
west
nile
flavivirus
isoformspecif
knockdown
cypa
cypb
cypc
doubl
knockdown
cypa
cypb
ppias
activ
cypa
shown
essenti
effect
replic
dengu
wnv
tang
show
cypa
directli
interact
protein
wnv
howev
interact
affect
enzymat
activ
vitro
consist
find
csa
shown
block
interact
cypa
wnv
suppress
viral
rna
synthesi
inhibit
broad
spectrum
rna
virus
nontox
concentr
role
cypb
replic
japanes
enceph
viru
jev
demonstr
rescu
jev
replic
express
wild
type
cypb
ppiasedefici
cypb
variou
mammalian
cell
endogen
cypb
suppress
find
support
find
csa
potent
inhibit
replic
jev
vitro
nonflavivirus
cyp
inhibit
demonstr
restrict
flaviviru
replic
role
cyp
virus
less
clear
convinc
argument
cyp
involv
replic
vaccinia
viru
vv
provid
demonstr
csa
analog
strong
bind
affin
cypa
potent
inhibitor
vv
replic
analog
weak
affin
cypa
lost
antivir
activ
subsequ
studi
reveal
incorpor
cypa
vv
virion
essenti
event
success
matur
similar
incorpor
cypa
viral
particl
report
vesicular
stomat
viru
sar
coronaviru
howev
case
addit
role
cypa
propos
novel
function
cyp
viral
entri
describ
human
papillomaviru
type
involv
cellsurfac
fraction
cypb
follow
viru
attach
serv
effect
conform
chang
capsid
protein
lead
effici
infect
incorpor
cypb
virion
measl
viru
mv
shown
import
requir
expand
trophism
viru
includ
epitheli
neuron
cell
neutral
antibodi
direct
receptor
cypa
cypb
serv
limit
infect
epitheli
cell
mv
inhibit
mv
infect
also
demonstr
treatment
csa
led
propos
mv
incorpor
cypb
cypa
matur
virion
cypb
serv
allow
effect
infect
express
epitheli
cell
role
cyp
replic
herp
simplex
viru
suggest
find
csa
inhibit
viru
product
vitro
howev
immunosuppress
properti
csa
need
taken
consider
assess
result
support
function
cyp
replic
numer
virus
identifi
evid
cyp
restrict
toward
viral
replic
report
cypa
shown
bind
protein
influenza
restrict
viral
replic
induc
ubiquitinproteosomedepend
degrad
protein
notabl
ppias
defici
cypa
protein
could
still
bind
inhibit
viral
replic
deplet
cypa
found
enhanc
replic
influenza
viru
vitro
similar
find
report
wu
result
studi
effect
cypa
rotaviru
replic
silenc
cypa
result
decreas
interferonb
product
increas
viral
replic
effect
report
independ
ppias
activ
cypa
role
cyp
signal
pathway
activ
follow
viral
infect
first
suggest
demonstr
cypb
involv
regul
knockdown
cypb
found
suppress
newcastl
diseas
virusinduc
phosphoryl
block
dimer
inhibit
product
interferonb
recent
report
hopkin
describ
novel
induct
type
iii
interferon
hcvinfect
patient
follow
treatment
nonimmunosuppress
cyp
inhibitor
result
point
possibl
role
cyp
virusinduc
block
innat
immun
respons
would
otherwis
serv
clear
infect
place
cyp
inhibit
potenti
import
immunotherapi
approach
virolog
factor
affect
cyclophilin
calcineurin
bind
cyp
bind
domain
csa
compris
residu
henc
alter
residu
tend
signific
effect
cyp
bind
modif
residu
cn
bind
domain
hand
influenc
cyp
bind
indirectli
effect
conform
often
exert
profound
affect
cn
bind
e
mebmt
group
posit
uniqu
resid
cyp
bind
domain
yet
sidechain
drape
across
csa
scaffold
ultim
cn
bind
domain
fig
gener
modif
mebmt
tend
decreas
cyp
bind
remov
alter
stereochemistri
group
reduc
activ
introduc
second
methyl
group
posit
likewis
remov
replac
cap
ester
also
reduc
potenc
one
case
cyp
bind
actual
improv
c
c
doubl
bond
replac
bioisoster
sulfur
atom
methiabmt
found
bind
cyp
affin
csa
csa
bind
cyp
affin
compar
csa
dmeser
csa
bind
cyp
threefold
greater
affin
csa
import
attribut
exploit
design
csabas
therapeut
essenti
featur
cyp
inhibitor
design
use
antivir
agent
immunosuppress
activ
due
cn
inhibit
reduc
remov
effect
achiev
modif
side
chain
meleu
residu
involv
tight
aromat
sandwich
cn
residu
trp
phe
fig
surprisingli
move
one
methyl
group
meleu
residu
give
meil
csa
found
remov
immunosuppress
activ
retain
tabl
view
welldescrib
loss
cypa
bind
potenc
result
esterif
mebmthydroxyl
point
import
appropri
substitu
sar
antivir
activ
hcv
data
yet
avail
deriv
compound
high
interest
evolv
includ
possess
optim
sar
substitut
cyp
bind
andor
drugabl
meleu
function
attenu
immunosuppress
potenti
also
modifi
improv
druglik
properti
diminish
immunosuppress
potenti
result
potent
antivir
scaffold
posit
success
modifi
yield
antivir
includ
posit
alisporivir
proceed
furthest
clinic
develop
build
data
show
replac
leucin
residu
valin
result
loss
immunosuppress
activ
along
metabol
data
csa
indic
demethyl
amid
meleu
major
clearanc
mechan
debiopharm
identifi
meala
etval
csa
alisporivir
potent
cypa
binder
good
antihiv
activ
drug
demonstr
good
hcv
activ
combin
ribavirin
activ
monotherapi
hcv
genotyp
combin
sar
modif
result
potent
antihiv
activ
homeleu
residu
result
potent
antihiv
antihcv
activ
nonimmunosuppress
shown
activ
multipl
hcv
genotyp
high
barrier
resist
less
inhibitori
csa
alisporivir
toward
key
transport
involv
bilirubin
control
find
lower
vitro
transport
interact
csa
alisporivir
like
import
diseas
hcv
polypharmaci
approach
like
alisporivir
repres
clinic
advanc
nonimmunosuppress
cyp
inhibitor
number
compar
structur
beyond
shown
tabl
appear
patent
literatur
mani
involv
modif
meleu
residu
figur
show
synthet
pathway
toward
alisporivir
effort
last
year
identifi
noncsabas
inhibitor
cyp
met
success
sanglifehrin
fig
natur
product
first
describ
shown
potent
inhibitor
cypa
deriv
sanglifehrin
describ
good
antihcv
activ
howev
compound
yet
progress
clinic
studi
conclus
cyp
inhibit
emerg
last
year
support
role
requir
immunosuppress
via
cn
inhibit
viabl
approach
toward
treat
wide
varieti
diseas
state
virolog
matur
host
cyp
clearli
hijack
sever
virus
enabl
effect
replic
cyp
inhibit
offer
promis
new
approach
antivir
therapi
addit
find
cyp
inhibit
play
role
uncloak
viru
hcv
immun
surveil
potenti
excit
howev
discoveri
effort
field
like
challeng
mani
vitro
viru
infect
screen
system
success
due
immunolog
defect
render
host
cell
permiss
viral
infect
discoveri
nonimmunosuppress
cyp
inhibitor
alisporivir
allow
cyp
inhibit
consid
diseas
state
wherein
immunosuppress
would
prohibit
furthermor
demonstr
good
oral
bioavail
ddi
potenti
clearli
indic
rel
larg
macrocycl
peptid
could
case
consid
druglik
biolog
cyp
continu
unfold
challeng
medicin
chemistri
discov
compound
select
inhibit
member
cyp
famili
use
tool
valid
role
cyp
diseas
state
lead
drug
discoveri
effort
csa
serv
admir
start
point
cyp
research
littl
select
within
cyp
famili
describ
deriv
compound
new
inhibitori
templat
begin
appear
may
deliv
improv
select
howev
applic
fragmentbas
screen
aid
avail
structur
data
support
locat
bind
allow
inhibitor
design
exploit
region
cyp
protein
differ
among
famili
member
